146
- De Wit M, Kvien T, Gossec L. Patient participation as an integral part of patient reported out-
comes development guarantees the representativeness of the patient voice: a case-study from
the fi eld of rheumatology. RMD Open. 2015;1(1), e000129. - European League Against R. Tools and products. 2015. http://www.eular.org/toolsproducts.
cfm. Accessed 4 Sep. 2015. - Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for
routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6. - Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves
joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-
reported outcomes of the adalimumab effectiveness in psoriatic arthritis trial. Ann Rheum Dis.
2007;66(2):163–8. - Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves
the health-related quality of life of patients with psoriasis: results of a phase iii randomized
clinical trial. J Am Acad Dermatol. 2005;53(5):887–9. - Katz PP. Introduction to special issue: patient outcomes in rheumatology, 2011. Arthritis Care
Res. 2011;63 Suppl 11:S1–3. - Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment
in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol.
2011;38(5):898–903. - Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffi n K, et al. The
development of candidate composite disease activity and responder indices for psoriatic arthri-
tis (grace project). Ann Rheum Dis. 2013;72(6):986–91. - Coates LC, Fransen J, Helliwell PS. Defi ning minimal disease activity in psoriatic arthritis: a
proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48–53. - Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis
using interventional trial data. Arthritis Care Res. 2010;62(7):965–9. - Tälli S, Etcheto A, Fautrel B, et al. Patient global assessment in psoriatic arthritis—what does
it mean? An analysis of 223 patients from the psoriatic arthritis impact of disease (PsAID)
study. Joint Bone Spine. 2016;83:335–40. - Arthritis R and Aging Medical Information System. http://aramis.Stanford.Edu/downloads/
haq%20instructions%20%28aramis%29%206-30-09.Pdf. Stanford: Stanford University. - Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, et al. Finalisation
and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite
measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis.
2011;70(6):935–42. - Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the
clinical importance of treatment outcomes in chronic pain clinical trials: impact recommenda-
tions. J Pain. 2008;9(2):105–21. - Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD. Occurrence and correlates of
fatigue in psoriatic arthritis. Ann Rheum Dis. 2009;68(10):1553–8. - Minnock P, Kirwan J, Veale D, Fitzgerald O, Bresnihan B. Fatigue is an independent outcome
measure and is sensitive to change in patients with psoriatic arthritis. Clin Exp Rheumatol.
2010;28(3):401–4. - Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness
therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis.
2007;66(7):936–9. - Husted JA, Tom BD, Farewell VT, Gladman DD. Longitudinal analysis of fatigue in psoriatic
arthritis. J Rheumatol. 2010;37(9):1878–84. - Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual ana-
log scales and longer fatigue questionnaires in 7760 patients. J Rheumatol.
2004;31(10):1896–902. - Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis.
Arthritis Rheum. 1980;23(2):137–45.
U. Kiltz et al.